SALT

UPSIDE Foods, formerly known as Memphis Meats, is a company headquartered in San Francisco, California, that specializes in producing cultured meat directly from animal cells. Founded in 2015 by Uma Valeti and Nicholas Genovese, the company focuses on developing products such as hot dogs, sausages, burgers, and meatballs without the need to raise and slaughter animals. This innovative approach to meat production requires significantly less caloric input, water, land, and energy compared to traditional methods, while also aiming to provide consumers with cleaner meat products that are free from harmful chemicals.

Tessera Therapeutics is an early-stage life sciences company focused on pioneering Gene Writing technology, which allows for the permanent modification of the human genome. This innovative approach enables scientists and clinicians to introduce therapeutic messages into the genome, offering a potential cure for diseases at their source. By building on recent advancements in gene therapy and gene editing, Tessera Therapeutics aims to address significant limitations in these areas, enhancing their applicability and effectiveness. Founded by Flagship Pioneering, the company is positioned to transform genetic medicine and improve patient care through its groundbreaking technology.

Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform.

Cambrian Biopharma is a multi-asset biotech R&D firm uniquely focused on a specific field of biomedical research: the biology of aging, also known as geroscience. We believe the future of medicine should be proactive and committed to extending our best years, not just reactive to certain diseases. As experts in the biology of age-related disease, it is our mission to assemble the world's best scientists to accelerate this paradigm shift. We are built on an emerging business model we call a "Distributed R&D Company" (or "DisCo"), partnering with academic geroscientists to build companies, conduct preclinical drug discovery, and manage clinical trials. Cambrian looks to discover and develop therapeutics that target the molecular damage that arises during aging and leads to chronic disease. Our approach is to build a diverse portfolio led by scientific rigor and data, not ego. Focusing on early-stage therapeutics, we collaborate with pioneering scientists to bring discoveries out of the lab and into the clinic as efficiently as possible. So far, we have launched 10 companies with leading geroscientists and have relationships with more than 100 geroscience-focused labs globally, translating to a toolkit for tech-transfer negotiations and rapid spinouts.

Gameto is a biotechnology company focused on addressing infertility and menopause-related challenges. Founded in 2020 and headquartered in New York, the firm employs a unique platform that utilizes proprietary combinations of transcription factors to create engineered ovarian cell lines. These cell lines are designed to replicate the functions of natural ovarian cells, allowing for the production and regulation of hormones essential for female reproductive health. By harnessing allogeneic human cellular derivatives, Gameto aims to develop therapeutic applications that can effectively treat conditions associated with accelerated ovarian aging and enhance assisted fertility options for women.